- Home
- GDL vs MDXH Comparison
GDL vs MDXH Comparison
Compare GDL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- MDXH
- Stock Information
- Founded
- GDL 2006
- MDXH 2003
- Country
- GDL United States
- MDXH Belgium
- Employees
- GDL N/A
- MDXH N/A
- Industry
- GDL Investment Managers
- MDXH
- Sector
- GDL Finance
- MDXH
- Exchange
- GDL Nasdaq
- MDXH Nasdaq
- Market Cap
- GDL 93.8M
- MDXH 84.6M
- IPO Year
- GDL N/A
- MDXH 2021
- Fundamental
- Price
- GDL $8.30
- MDXH $2.18
- Analyst Decision
- GDL
- MDXH Buy
- Analyst Count
- GDL 0
- MDXH 1
- Target Price
- GDL N/A
- MDXH $6.00
- AVG Volume (30 Days)
- GDL 11.2K
- MDXH 62.0K
- Earning Date
- GDL 01-01-0001
- MDXH 08-20-2025
- Dividend Yield
- GDL 6.02%
- MDXH N/A
- EPS Growth
- GDL N/A
- MDXH N/A
- EPS
- GDL N/A
- MDXH N/A
- Revenue
- GDL N/A
- MDXH $94,507,000.00
- Revenue This Year
- GDL N/A
- MDXH $23.51
- Revenue Next Year
- GDL N/A
- MDXH $17.68
- P/E Ratio
- GDL N/A
- MDXH N/A
- Revenue Growth
- GDL N/A
- MDXH 25.46
- 52 Week Low
- GDL $7.65
- MDXH $1.35
- 52 Week High
- GDL $8.13
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- GDL 49.06
- MDXH 52.06
- Support Level
- GDL $8.25
- MDXH $2.09
- Resistance Level
- GDL $8.37
- MDXH $2.22
- Average True Range (ATR)
- GDL 0.07
- MDXH 0.10
- MACD
- GDL -0.01
- MDXH -0.01
- Stochastic Oscillator
- GDL 36.69
- MDXH 59.52
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.